SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery

Dijkstra, B. M.; Motekallemi, A.; den Dunnen, W. F. A.; Jeltema, J. R.; van Dam, G. M.; Kruyt, F. A. E.; Groen, R. J. M.

Published in:
Acta Neurochirurgica

DOI:
10.1007/s00701-018-3575-z

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Dijkstra, B. M., Motekallemi, A., den Dunnen, W. F. A., Jeltema, J. R., van Dam, G. M., Kruyt, F. A. E., & Groen, R. J. M. (2018). SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery. Acta Neurochirurgica, 160(8), 1539-1546. https://doi.org/10.1007/s00701-018-3575-z

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 23-05-2021
SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery

B. M. Dijkstra 1 · A. Motekallemi 2 · W. F. A. den Dunnen 3 · J. R. Jeltema 1 · G. M. van Dam 4 · F. A. E. Kruyt 5 · R. J. M. Groen 1

Received: 28 March 2018 / Accepted: 23 May 2018 / Published online: 1 June 2018
© The Author(s) 2018

Abstract

Background Meningiomas are the most frequently occurring primary intracranial tumours in adults. Surgical removal can only be curative by complete resection; however surgical access can be challenging due to anatomical localization and local invasion of bone and soft tissues. Several intraoperative techniques have been tried to improve surgical resection, including intraoperative fluorescence guided imaging; however, no meningioma-specific (fluorescent) targeting has been developed yet. Here, we aimed to identify the most promising biomarkers for targeted intra-operative fluorescence guided meningioma surgery.

Methods One hundred forty-eight meningioma specimens representing all meningioma grades were analysed using immunohistochemistry (IHC) on tissue microarrays (TMAs) to determine expression patterns of meningioma biomarkers epithelial membrane antigen (EMA), platelet-derived growth factor β (PDGF-β), vascular endothelial growth factor α (VEGF-α), and somatostatin receptor type 2 (SSTR-2). Subsequently, the most promising biomarker was selected based on TArget Selection Criteria (TASC). Marker expression was examined by IHC in 3D cell culture models generated from freshly resected tumour material.

Results TMA-IHC showed strongest staining for SSTR-2. All cases were positive, with 51.4% strong/diffuse, 30.4% moderate/diffuse and only 18.2% focal/weak staining patterns. All tested biomarkers showed at least weak positivity in all meningiomas, regardless of WHO grade. TASC analysis showed that SSTR-2 was the most promising target for fluorescence guided imaging, with a total score of 21 (out of 22). SSTR-2 expression was determined on original patient tumours and 3D cultures of three established cultures.

Conclusions SSTR-2 expression was highly sensitive and specific in all 148 meningiomas, regardless of WHO grade. According to TASC analysis, SSTR-2 is the most promising receptor for meningioma targeting. After establishing in vitro meningioma models, SSTR-2 cell membrane expression was confirmed in two of three meningioma cultures as well. This indicates that specific fluorescence in an experimental setting can be performed for the further development of targeted fluorescence guided meningioma surgery and near-infrared fluorescent tracers targeting SSTR-2.

Keywords Intracranial meningioma · Fluorescence guided surgery · Intraoperative imaging · Somatostatin receptor subtype 2 · Biomarker

Abbreviations

EMA Epithelial membrane antigen
IHC Immunohistochemistry
PDGF-β Platelet-derived growth factor receptor beta
SSTR-2 Somatostatin receptor type 2
T/N Tumour-to-normal tissue ratio
TASC TArget Selection Criteria
TMA Tissue microarray
VEGF-α Vascular endothelial growth factor A
Introduction

Meningiomas are the most frequently occurring intracranial tumours in adults, accounting for approximately one third of cases [37]. They are classified by the World Health Organization (WHO) into three malignancy grades with 15 histologic subtypes [26]. Treatment is usually only curative with complete surgical resection [6, 50] and aims for both complete tumour removal and preservation of neurological function [29, 55]. Although mostly benign and slow growing, all meningiomas can pose surgical challenges due to anatomical localization and local invasion of bone and soft tissues, leading to residual tumour tissue. Incomplete resection is one of the risk factors for recurrence [6].

One of the proposed techniques to facilitate resection is intraoperative fluorescence-guided imaging. Several fluorescent dyes (5-aminolevulinic acid, fluorescein, and indocyanine green) have been tried [1, 10, 14, 25, 33]; however, evidence regarding the benefit of applying these dyes is unavailable. Furthermore, fluorescent dyes currently lack specificity. The concept of targeted fluorescence is appealing, due to high sensitivity and specificity rates. Identification of meningioma-specific biomarkers is a first and essential step in this concept. Comparable targeted fluorescent techniques have been established in other tumour types, e.g. in ovarian carcinoma [17, 53] and peritoneal metastases of colorectal carcinomas [18] targeting αvβ3-integrin or folate receptor α and VEGF-α, respectively. For the development of a similar approach in meningioma surgery, various biomarkers have been suggested, including epithelial membrane antigen (EMA), platelet-derived growth factor beta (PDGF-β), vascular endothelial growth factor A (VEGF-α), and somatostatin receptor type 2 (SSTR-2) [3, 5, 9, 11, 12, 16, 19, 21, 28, 30, 32, 38, 39, 43–45, 48, 52, 56]. However, the suitability of these markers for fluorescence-guided imaging meningioma surgery has not yet been investigated.

In this study, we aimed to make a step-wise approach: (1) identifying meningioma-specific candidate biomarkers (EMA, PDGF-β, VEGF-α and SSTR-2); (2) selecting the most promising tumour-specific marker; and (3) confirming its expression in in vitro cultures derived from fresh meningioma specimens.

Methods and materials

Part 1: identifying meningioma-specific candidate biomarkers

Specimens of previously untreated, primary intracranial meningiomas resected between January 2006 and December 2010 were retrospectively analysed for the expression of four potential biomarkers (i.e. EMA, PDGF-β, VEGF-α and SSTR-2). A total number of 148 meningioma specimens were available for analysis. All patient data were anonymized according to the regulations of the Medical Ethical Research Committee of the University Medical Center Groningen.

Meningioma samples were examined using tissue microarrays (TMAs). TMA sections were deparaffinised with xylene, rehydrated in ethanol, and rinsed in distilled water. After antigen retrieval with a Tris-EDTA or Tris-HCl buffer, endogenous peroxidase was blocked for 30 min using a 0.1% H2O2 PBS solution. Respective antibody staining was performed at room temperature. The selected primary antibodies of interest were anti-EMA (mouse monoclonal, Dako), anti-PDGF-β (rabbit polyclonal, Santa Cruz), anti-VEGF-α (rabbit polyclonal, Santa Cruz) and anti-SSTR-2 (rabbit monoclonal, Epitomics). We used normal cerebellar and anterior pituitary tissue as positive controls. Additionally, we omitted the primary antibody and used IgG controls. Secondary and tertiary antibody staining was performed for 30 min. All sections were subjected to a 3,3-diaminobenzidine solution for 10 min and finally counterstained with haematoxylin for 2 min, dehydrated in ethanol, cleared, mounted and cover slipped.

For immunohistochemical (IHC) evaluation, TMA sections were scanned with an ultra-resolution digital scanner ScanScope CS®, Aperio® with ×20 image magnification and evaluated with Aperio ImageScope® software. Each tissue core of the TMA section was scored using the following scoring method: negative, (0); weak/focal staining, (1); moderate/diffuse staining, (2); strong/diffuse staining, (3). Two authors (AM and WFD) independently evaluated tissue cores and in case of discrepant scores, consensus was reached by way of discussion between both evaluators. Cores were regarded as non-informative and consequently dismissed when > 50% tissue was lost or presented inappropriate amounts of collagen staining. Tumour specimens which were represented by less than two complete cores were excluded. A mean score was calculated for each specimen and specimens with an average score of 1 were considered positive, whereas specimens with a mean score of ≥2 were summarized as “high score”.

Statistical analysis

All statistical analyses were performed using IBM® SPSS® Statistics 20. Spearman rank-order correlation was used to find correlation between targets and WHO classifications. All reported P values were two sided and a value of $P \leq 0.05$ was considered as statistically significant.

Part 2: selecting the most promising tumour-specific marker

To investigate the usefulness of these markers for intraoperative fluorescence-guided imaging, the Target Selection Criteria (TASC) [54] were utilized for the selection of the most promising targets, as depicted in Table 1.
Part 3: confirming expression in in vitro cultures

Meningioma 3D cell culture models were established to provide an accurate model for the disease [13, 24]. Surgical left-over fresh tumour tissue was washed with ice-cold PBS and mechanically dissociated. After adding 15 to 20 ml accutase, tissue incubated for 30 min at room temperature. The suspension was passed through a 70-μm cell strainer to procure single cells and pelleted. Cells were seeded in T75 flasks with medium containing DMEM/F12 supplemented with 2% B27, 20 ng/ml EGF, 20 ng/ml bFGF [22], and 2% pen/strep.

For IHC analyses, 3D cultures were dissociated with accutase and cytospun. Subsequently, cells were fixated with 4% formaldehyde, washed with PBS and underwent a blocking step with 1% H2O2 in PBS for 10 min. Cells were then incubated with anti-SSTR-2 (1:100; MAB4224, R&D systems) for 1 h, followed by incubation of the corresponding secondary and tertiary antibodies diluted at 1:50 in PBS with 1% BSA and 1% AB serum for 30 min. Lastly, cells were incubated with 5% 3-amino-9-ethylcarbazole diluted in acetate buffer with 0.1% hydrogen peroxide for 10 min, counterstained with haematoxylin for 2 min, and mounted with Kaiser’s glycerin for microscopic examination using a Leica DM 3000 microscope.

Results

Part 1: identifying meningioma-specific candidate biomarkers

Patient characteristics

Patient and tumour characteristics are summarized in Table 2. The age at surgery ranged from 4 to 79 years. Tumour specimens were obtained from 52 male and 96 female patients. Our study revealed 124 WHO I (83.8%), 22 WHO II (14.9%) and 2 WHO III (1.4%) meningiomas. All tested biomarkers showed at least weak positivity in all meningiomas, regardless of WHO grade. No association was found between WHO grade and the expression rates of the potential targets using Spearman rank order correlation (Table 3).

| Criteria | Characteristics | Score |
|----------|-----------------|-------|
| I        | Extracellular protein localization | Bound to cell surface (receptor) | 5 |
|          |                  | In close proximity of tumour cell | 3 |
| II       | Diffuse upregulation through tumour tissue | 4 |
| III      | Tumour-to-normal ratio > 10 | 3 |
| IV       | Percentage upregulation in patients | >90% | 6 |
|          |                  | 70–89% | 5 |
|          |                  | 50–69% | 3 |
|          |                  | 10–49% | 0 |
| V        | Previously successfully imaged in vivo | 2 |
| VI       | Enzymatic activity | 1 |
| VII      | Internalization | 1 |
| Maximum: |                  | 22 |
| Potential target ≥18 |

Table 1 TASC scoring system

| Target | Spearman correlation (p value) |
|--------|-------------------------------|
| EMA    | .498                          |
| VEGF-α | .909                          |
| PDGFR-β| .255                          |
| SSTR-2 | .647                          |

Table 2 Patient and tumour specimen characteristics

|                      | Men       | Women     |
|----------------------|-----------|-----------|
| Percent (n (%))      | 52 (35.1) | 96 (64.9) |
| Age (years) (mean (range)) | 47.2 (4.4–79.8) | 52.4 (4.2–77.5) |
| Meningioma grade (n (%*)) |          |           |
| WHO I                | 38 (25.7) | 86 (58.1) |
| WHO II               | 12 (8.1)  | 10 (6.8)  |
| WHO III              | 2 (1.4)   | 0 (0.0)   |

*Percentage of all meningiomas
Target expression in TMA sections

Both cerebellar and anterior pituitary tissue showed SSTR-2-positivity. Additionally, white matter in the cerebellar tissue was SSTR-2 negative, as expected. Omission of the primary antibody revealed no SSTR-2 staining and aspecific binding with IgG was not observed.

TMA-IHC results are summarized in Table 4. Of all TMA meningioma specimens (588), 99.8% was IHC-positive for the investigated targets with at least two or more valid tissue cores. The number of non-informative/invalid cores was low for PDGFR-β (0.7%) and VEGF-α (2.0%) and all cores for EMA and SSTR-2 were valid. The IHC staining score for SSTR-2 was the most robust, resulting in positivity for SSTR-2 in all specimen: moderate/diffuse or strong/diffuse positivity in 81.8% (“high score”) and focal/weak positivity in only 18.2% of all cases. Representative examples illustrating SSTR-2 expression are shown in Fig. 1.

Part 2: selecting the most promising tumour-specific marker

The selected markers were evaluated using TASC based on IHC-TMA results (Table 5). Using these criteria, SSTR-2 is the most promising target for intra-operative use with a total TASC score of 21. In addition, EMA, PDGFR-β and VEGF-α seem to be high potential targets with TASC scores of 20, 20 and 18, respectively.

Part 3: confirming expression in in vitro cultures

Generating meningioma cultures

In vitro cultures were established to further explore the potential of SSTR-2 as a meningioma-specific marker in a translational model. After processing the freshly resected material, 11 of 22 cultures (50%) generated 3D cultures after 7 days (Fig. 2, top panel). However, growth decreased after three to four passages. A selection of three cultures named MgG24, MgG26 and MgG27 was characterized in more detail. These cultures originated from three female patients with a mean age of 65.7 years (range 60–77; SD 9.8). All meningiomas were WHO grade I, with one transitional and two meningothelial meningiomas (Fig. 2, middle panel). Two meningiomas were located at the convexity and one at the skull base (Fig. 2, bottom panel).

SSTR-2 expression in in vitro meningioma cultures

SSTR-2 expression was determined on original patient tumours and 3D cultures of the three established cultures. All patient tumours were strongly positive for SSTR-2 at the cell

---

Table 4 Summary of IHC results

| Target | Valid cores | Weak/focal (%) | Moderate/ diffuse (%) | Strong/diffuse (%) | High score* (%) |
|--------|-------------|----------------|----------------------|-------------------|----------------|
| EMA    | 148         | 16 (10.8)      | 113 (76.4)           | 19 (12.8)         | 132 (89.2)     |
| VEGF-α | 145         | 45 (31.0)      | 93 (64.1)            | 7 (4.8)           | 100 (69.0)     |
| PDGFR-β| 147         | 34 (23.1)      | 107 (72.8)           | 6 (4.1)           | 113 (76.9)     |
| SSTR-2 | 148         | 27 (18.2)      | 45 (30.4)            | 76 (51.4)         | 121 (81.8)     |

Shown percentages are valid ratios for the respective target.
*Defined as moderate/diffuse or strong/diffuse staining.

Fig. 1 Representative images of SSTR-2 stained TMA-IHC cores and scoring approach. Shown are weak/focal (left), moderate/diffuse (middle), and strong/diffuse (right) staining patterns.
membrane (Fig. 3, top panel). However, of the dissociated 3D cultures, only MgG24 and MgG26 are SSTR-2 positive with a cell membranous staining. It should be noted that not all cells are (equally) positive in both cultures: some cells show no or weak SSTR-2 positivity, whereas in other cells, the staining is strongly positive (Fig. 3, bottom panel).

| TASC item | Target | I Localization | II Expression pattern* | III T/N ratio | IV Upregulation in patients* (%) | V In vivo imaging | VI Enzymatic activity | VII Internalization | Score |
|-----------|--------|----------------|------------------------|---------------|---------------------------------|------------------|-----------------------|---------------------|-------|
| EMA       | Transmembrane | Diffuse | High 100 | Yes [34, 49] | ND | ND | 20 |
| VEGF-α    | Secreted  | Diffuse | High 100 | Yes [35, 36, 47] | ND | ND | 18 |
| PDGFR-β   | Transmembrane | Diffuse | High 100 | Yes [15] | ND | ND | 20 |
| SSTR-2    | Transmembrane | Diffuse | High 100 | Yes [21, 23, 52] | Yes [46] | ND | 21 |

ND, not described; T/N ratio, tumour-to-normal tissue ratio

*Expression patterns are considered “diffuse”, if moderate/diffuse or strong/diffuse staining is present in more than 66% of included cases

Fig. 2 Top panel shows micrographs of 3D meningioma cultures with × 10 magnification. Middle panel depicts micrographs of H&E stained original patient tumour at × 40 magnification. Bottom panel are gadolinium-enhanced MRI scans. 3D cultures showed aggregated cell formation into a sphere. H&E stained tumour samples confirmed the diagnosis of meningioma in all three cases. MRI scans revealed meningiomas at the convexity and skull base.
Discussion

The first aim of this study was to identify the expression pattern of a series of preselected markers (EMA, PDGF-β, VEGF-α and SSTR-2) in meningiomas using TMA-IHC, which resulted in the analysis of a large collection of tested meningioma samples. We confirmed previous findings regarding meningioma biomarkers [3, 5, 9, 11, 12, 16, 19, 21, 28, 30, 32, 38, 39, 43–45, 48, 52, 56]. All investigated markers tested positive in all meningiomas, regardless of WHO grade. However, SSTR-2 expression was especially robust with a high score in 81.8% of all cases. SSTR-2 was also highly specific and sensitive. These findings are in line with previous studies [12, 30, 48]. Subsequently we focused on the second aim of this study, namely, identifying the most promising tumour-specific marker for intraoperative application.

Applying TASC, SSTR-2 was found to be superior when compared to the other three biomarkers. Although TASC was initially developed for target selection in colorectal cancer and has not yet been validated in other tumours, the principle is also applicable to other tumour types as it is based on biomarker characteristics and not on a specific tumour type. This tool (TASC) is the first structured method to determine the suitability of a biomarker for intraoperative imaging. As a major advantage, TASC provides an objective score by considering available evidence.

The potential of SSTR-2 was analysed in a translational model using newly generated patient-derived 3D meningioma cultures. In two of three tested cultures, SSTR-2 expression was present at the cell membrane, emphasizing the possibility of SSTR-2 as a potential target for fluorescence guided imaging. One culture was SSTR-2 negative, which may be due to a technical issue with reduced culture viability. Indeed, the original patient tumour was SSTR-2 positive. Further research is warranted to investigate this issue further. As far as we know, this is the first time that the expression SSTR-2 has been determined in in vitro meningioma cultures using IHC. Several limitations became apparent when using this model. The cultures could be subcultured for a limited number of passages: cell growth decreased after three to four passages, similar to a previous report [51]. Moreover, the generated in vitro models are all originating from WHO grade I meningiomas. Although patients with high grade lesions may benefit the most from intraoperative imaging, WHO I meningiomas are still a representable model as SSTR-2 is expressed in all meningiomas, regardless the grade [30, 48].

The present study is an essential first step towards the development of meningioma-specific intraoperative fluorescence-guided imaging. Future steps should consist of binding studies with fluorescent dyes (preferably near-infrared dyes, such as IRDye 800CW) with SSTR-2 analogues (e.g. octreotate). These have already been used in targeted therapy for recurrent meningiomas [2, 8, 42] and their application in theranostics and PET-scanning has been demonstrated [19, 21, 52]. IRDye 800 CW has undergone a microdosing study [27] and has been applied in various clinical trials [57]. Further validation is needed by testing a target-directed imaging tool in vitro for proof of concept, and subsequently in in vivo animal models using xenograft mouse models. Animal models have been successfully applied previously, using fresh patient-derived material [20, 31, 41, 51] or immortalized meningioma cell lines [4, 7, 40, 41], with higher grade meningiomas yielding a higher success rate.
Such models are needed for translational research to assess SSTR-2 guided intra-operative meningioma surgery.

**Conclusions**

The present results highlight the potential of SSTR-2 as a high potential target for fluorescence-guided imaging. We identified SSTR-2 as the most suitable biomarker for targeted fluorescence-guided meningioma surgery by applying TMA-IHC and TASC. SSTR-2 was highly sensitive and specific and was expressed in all meningiomas in our large patient sample cohort, regardless of WHO grade. Furthermore, we established freshly generated in vitro meningioma models closely reflecting the original patient tumour and confirmed SSTR-2 expression in three meningioma cultures, which marks the first and essential step towards future in vitro experiments (tumour-cell imaging with fluorescently labelled SSTR-2 receptor markers) and in vivo experiments (meningioma identification in a mouse model). Further preclinical studies need to be performed to further develop the concept for targeted fluorescence-guided meningioma surgery.

**Compliance with ethical standards**

**Conflict of interest**  The authors declare that they have no conflict of interest.

**Ethical approval**  For this type of study formal consent is not required.

**Animal experiments**  This article does not contain any studies with human participants or animals performed by any of the authors.

**Open Access**  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Akçakaya MO, Göker B, Kasımcıoğlu MK, Kırs T (2017) Use of sodium fluorescein in meningioma surgery performed under the YELLOW-560 nm surgical microscope filter: feasibility and preliminary results. World Neurosurg 87(5–6):1319–1326
2. Albers AR, O’Dorisio MS (1996) Clinical use of somatostatin analogues in paediatric oncology. Digestion 57(Suppl 1):38–41
3. Andrae N, Kirches E, Hartig R, Haase D, Keilhoff G, Kalinski T, Mawrin C (2012) Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells. Eur J Cancer 48(12):1831–1841
4. Baia G, Slocum A, Hyer J, Misra A, Sehati N, VandenBerg S, Feuerstein B, Deen D, McDermott M, Lal A (2006) A genetic strategy to overcome the senescence of primary meningioma cell cultures. J Neuro-Oncol 78(2):113–121
5. Barresi V (2011) Angiogenesis in meningiomas. Brain Tumor Pathol 28(2):99–106
6. Campbell BA, Jambh A, Maguire JA, Toyota B, Ma R (2009) Meningiomas in 2009: controversies and future challenges. Am J Clin Oncol 32(1):73–85
7. Cargioli TG, Ugur HC, Ramakrishna N, Chan J, Black PM, Carroll RS (2007) Establishment of an in vivo meningioma model with human telomerase reverse transcriptase. Neurosurgery 60(4):750–760
8. Collamat F, Pepe A, Bellini F et al (2015) Toward radioguided surgery with β- decays: uptake of a somatostatin analogue, DOTATOC, in meningioma and high-grade glioma. J Nucl Med 56(1):3–8
9. Colls DM, Atkinson RD, Burnett ME (2007) Review of meningioma histopathology. Neurosurg Focus 23(4):E3
10. Da Silva CE, Duval V, da Silva CE, Braga JL, da Silva SD, da Silva JL (2014) Skull Base Meningiomas and cranial nerves contrast using sodium fluorescein: a new application of an old tool. J Neurol Surg B Skull Base 75(4):255–260
11. De Menis E, Tulipano G, Villa S, Bilicci D, Bonfanti C, Pollara P, Pauletto P, Giustina A (2003) Development of a meningioma in patient with acromegaly during octreotide treatment: are there any causal relationships? J Endocrinol Invest 26(4):359–363
12. Dutour A, Kumar U, Panetta R, Ouaffik L, Fina F, Sasi R, Patel YC (1998) Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer 76(5):620–627
13. Edmondson R, Broglie JJ, Adcock AF, Yang L (2014) Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol 12(4):207–218
14. Foster N, Eljamel S (2016) ALA-induced fluorescence image guided surgery of meningiomas: a meta-analyses. Photodiagn Photodyn Ther 15:73–78
15. Gekas AP, Pillarsetty NK, Punzalan B, Khan N, Smith-Jones P, Larson SM (2011) In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib. J Nucl Med 52(8):1301–1307
16. Hanfl S, Canoll P, Bruce JN (2010) A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neuro-Oncol 99(3):433–443
17. Harlaar NJ, Kelder W, Sarantopoulos A, Bart J, Themelis G, van der Zee M (2013) Real-time near infrared fluorescence (NIRF) intra-operative imaging in ovarian cancer using an αvβ3-integrin targeted agent. Gynecol Oncol 128(3):590–595
18. Harlaar NJ, Koller M, de Jongh SJ et al (2016) Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study. Lancet Gastroenterol Hepatol 1(4):283–290
19. Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, Mäcke HR, Hofman MS, Debus J, Haberkorn U (2011) PET imaging of somatostatin receptors using [68Ga]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 42(7):1053–1056
20. Huang D-Y, Sytwu H-K, Huang S-M, Chang C, Ma H-I (2011) Isolation and characterization of tumor stem-like cells from human meningiomas. J Neuro-Oncol 104(1):45–53
21. Hurst RD, Modlin LM (1993) Use of radiolabeled somatostatin analogs in the identification and treatment of somatostatin receptor-bearing tumors. Digestion 54(Suppl 1):88–91
22. Joseph JV, Conroy S, Tomar T et al (2014) TGF-β is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion. Cell Death Dis 5:e1443
23. Körner M, Waser B, Schonbrunn A, Beren Reubi JC (2012) Somatostatin receptor subtype 2A immunohistochemistry using a
new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol 36(2):242–252

24. Lee J, Kotliarova S, Kotliarov Y et al (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the genotype of tumor stem cells than do serum-cultured cell lines. Cancer Cell 9(5):391–403

25. Lee JYK, Pierce JT, Thawani JP, Zeh R, Nie S, Martinez-Lage M, Singhal S (2017) Near-infrared fluorescent image-guided surgery for intracranial meningioma. J Neurosurg:1–11

26. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820

27. Marshall MV, Draney D, Sevick-Muraca EM, Olive DM (2010) Statistical report: primary brain and central nervous system tumors. Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors. J Neurol Sci 131(6):803–820

28. Mauro A, Di Sapio A, Mocellini C, Schiffer D (1995) Control of angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. Acta Neuropathol 130(3):441–450

29. Marshall MV, Draney D, Sevick-Muraca EM, Olive DM (2010) Statistical report: primary brain and central nervous system tumors. Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors. J Neurol Sci 131(6):803–820

30. Menke JR, Raleigh DR, Gown AM, Thomas S, Perry A, Tihan T (2015) Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Am J Surg Pathol 131(2):135–143

31. Michelhaugh SK, Guastella AR, Varadarajan K et al (2015) Development of patient-derived xenograft models from a spontaneously immortal low-grade meningioma cell line, KCI-MENG1. J Health Serv Res Policy 16(1):62–64

32. Miller R, DeCandio ML, Dixon-Mah Y, Giglio P, Vandergrift WA, Banik NL, Patel SJ, Varma AK, Das A (2014) Molecular targets and treatment of meningioma. J Neurol Neurosurg Psychiatry 20(1):22–26

33. Motekallemi A, Jeltema H-R, Metzemaekers JDM, van Dam GM, Crane LMA, Groen RJM (2015) The current status of 5-ALA fluorescence-guided resection of intracranial meningiomas—a critical review. Neurosurg Rev 38(4):619–628

34. Muguruma N, Ito S (2008) Labeled anti-mucin antibody detectable by infrared-fluorescence endoscopy. Cancer Biomark 4(6):321–328

35. Nagengast WB, de Vries EGE, Hospers GAP, Mulder NH, de Jong RL, Hollema H, Browsers AH, von Dongen GA, Perk LR, Lab-de Hoeve MN (2007) In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48(8):1313–1319

36. Ostrom QT, Gittleman H, Fiolup J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kuchloch C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology 17(Suppl 4):iv62

37. Panagopoulos AT, Lancellotti CLP, Veiga JCE, de Aguiar PHP, Colquhoun A (2008) Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neuro-Oncol 89(1):73–87

38. Pfister C, Pfrommer H, Tagatgha BS, Rosser F (2012) Vascular endothelial growth factor factor signals through platelet-derived growth factor receptor β in meningiomas in vitro. Br J Cancer 107(10):1702–1713

39. Pfüttmann S, Senner V, Braunh S, Hillmann B, Exeler R, Rickert CH, Paulus W (2005) Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Invest 85(9):1163–1171

40. Radel BT, Couldwell WT, Gillespie DL, Wendl MM, Whang K, Jensen RL (2008) A comparison of the cell lines used in meningioma research. Surg Neurol 70(3):295–307

41. Rammo R, Rock A, Transou A, Raghunathan A, Rock J (2016) Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease. J Neurosurg 124(2):496–500

42. Reubi JC, Laisse JA (1995) Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sci 16(3):110–115

43. Reubi JC, Maurer R, Klijn JG, Stefanko SZ, Fockens JA, Blaauw G, Blankenstein MA, Lamberts SWJ (1986) High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab 63(2):433–438

44. Reubi JC, Schaefer JC, Waser B, Mengod G (1994) Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 54(13):3455–3459

45. Rinne P, Hellberg S, Kugel M et al (2016) Comparison of somatostatin receptor 2-targeting PET tracers in the detection of mouse atherosclerotic plaques. Mol Imaging Biol 18(1):99–108

46. Scheer MGW, Stollman TH, Boerman OC, Verrijk K, Sweep FC, Leenders WPJ, Ruers TJM, Oven WJG (2008) Imaging liver metastases of colorectal cancer patients with radiolabeled bevacizumab: lack of correlation with VEGF-A expression. Eur J Cancer 44(13):1835–1840

47. Schulz S, Pauli SU, Schulz S, Händel M, Dietzmann K, Firsching R, Höllt V (2000) Immunohistochemical determination of somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 6(5):1865–1874

48. Shahbazi-Gahrouei D (2009) Novel MR imaging contrast agents for cancer detection. J Res Med Sci 14(3):141–147

49. Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20(1):22–39

50. Tang H, Gong Y, Mao Y et al (2012) CD133-positive cells might be responsible for efficient proliferation of human meningioma cells. J Mol Cell Mol Biol 13(5):6424–6439

51. Ulrich M, Bergmann R, Peitzsch M et al (2016) Multimodal somatostatin receptor theranostics using [(64)Cu]Cu-(Tyr(3))octreotate and AN-238 in a mouse pheochromocytoma model. Theranostics 6(5):650–665

52. Van Dam GM, Themelis G, Crane LMA et al (2011) Intraoperative somatostatin receptor theranostics using [(64)Cu]Cu-/(177)Lu-Lu-DOTA-(Tyr(3))octreotate and AN-238 in a mouse pheochromocytoma model. Theranostics 6(5):650–665

53. Van Dam GM, Themelis G, Crane LMA et al (2011) Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med 17(10):1315–1319

54. Van Oosten M, Crane LMA, Bart J, van Leeuwen FW, van Dam GM (2011) Selecting potential targetable biomarkers for imaging purposes in colorectal cancer using Target Selection Criteria (TASC): a novel target identification tool. Transl Oncol 4(2):71–82

55. Whitley IR, Smith C, Navoo P, Collie D (2004) Meningiomas. Lancet 363(9420):1535–1543

56. Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K (2000) Recurrence of meningiomas. Cancer 89(5):1102–1110

57. Zhang RR, Schroeder AB, Grudzinski JJ, Warram JM, Pinchuk AN, Eliceiri KW, Kuo JS, Weichert JP (2017) Beyond the margins: real-time detection of cancer using targeted fluorophores. Nat Rev Clin Oncol 14(6):347–364